B-cell Small Lymphocytic Lymphoma Recurrent (DBCOND0051780)

Identifiers

Synonyms

Recurrent B-cell small lymphocytic lymphoma / Recurrent Small Lymphocytic Lymphoma / B-cell small lymphocytic lymphoma recurrent / Small lymphocyte B lymphoma (Lukes-Collins Classification) recurrent

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01317901	A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma	Bendamustine Otlertuzumab Rituximab	treatment	1	completed
NCT04892277	CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT04578600	CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	Azacitidine Lenalidomide Obinutuzumab	treatment	1	active_not_recruiting
NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Hyaluronidase (human recombinant) Polatuzumab vedotin Rituximab Venetoclax	treatment	2	terminated
NCT00489203	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	Beclomethasone dipropionate Methotrexate Tacrolimus	supportive_care	2	completed
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	Palifermin	supportive_care	Not Available	completed
NCT01748721	MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma	Ontuxizumab	treatment	1	completed
NCT01589302	PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia	Ibrutinib Tyrosine	treatment	2	active_not_recruiting
NCT01126502	Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia	Alvespimycin	treatment	1	terminated
NCT00079443	FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma	Fludarabine Rituximab Romidepsin	treatment	2	terminated
NCT00089154	Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Apolizumab	treatment	2	completed
NCT01116154	Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	Lenalidomide Vorinostat	treatment	1	terminated
NCT00006251	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT02568553	Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma	Blinatumomab Lenalidomide Muromonab	treatment	1	active_not_recruiting
NCT00890747	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Sunitinib	treatment	1	completed
NCT00293345	3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma	Gemcitabine Triapine	treatment	1	completed
NCT01258998	Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma	No drug interventions	treatment	2	completed
NCT00054483	Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction	Bortezomib Bortezomib D-mannitol	basic_science	1	completed
NCT00608361	Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery	Dasatinib	treatment	1	completed
NCT01619761	NK Cells in Cord Blood Transplantation	Cyclophosphamide Fludarabine Lenalidomide Mechlorethamine Mycophenolate mofetil Natural Killer Cell Rituximab Tacrolimus	treatment	1	unknown_status
NCT01045928	Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Lenalidomide Rituximab	treatment	1	terminated
NCT01129193	AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma	AR-42	treatment	1	completed
NCT01177371	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma	Busulfan Cyclophosphamide Cyclosporine Methotrexate Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT01254578	Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers	Lenalidomide	treatment	1	completed
NCT03579888	CD19-Specific T Cells Post AlloSCT	Cyclophosphamide Fludarabine	treatment	1	terminated
NCT00082888	Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma	Tipifarnib	treatment	2	completed
NCT01567709	Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma	Alisertib Vorinostat	treatment	1	completed
NCT01076556	Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Alvocidib Cyclophosphamide Rituximab	treatment	1	terminated
NCT00354185	PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma	Belinostat Tanespimycin	treatment	1	terminated
NCT00068315	Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	Bortezomib Bortezomib D-mannitol Fludarabine Rituximab	treatment	1	completed
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT02160015	Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery	Ibrutinib Lenalidomide Rituximab	treatment	1	active_not_recruiting
NCT04169737	Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Acalabrutinib Obinutuzumab Tyrosine Venetoclax	treatment	2	recruiting
NCT01805037	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	Brentuximab vedotin Rituximab	treatment	1 / 2	terminated
NCT00118352	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT01886859	Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Ibrutinib Lenalidomide	treatment	1	completed
NCT02225275	Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Lenalidomide Obinutuzumab	treatment	2	terminated
NCT00003970	Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma	Irinotecan	treatment	1	completed
NCT00723099	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00005799	Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	Cyclosporine Fludarabine Mycophenolate mofetil Therapeutic allogeneic lymphocytes	treatment	Not Available	completed
NCT03246906	Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation	Cyclophosphamide Cyclosporine Mycophenolate mofetil Sirolimus	treatment	2	active_not_recruiting
NCT01369849	Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Bendamustine Rituximab	treatment	1 / 2	completed
NCT01815749	Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma	No drug interventions	treatment	1	active_not_recruiting
NCT04995536	CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL	No drug interventions	treatment	1	withdrawn
NCT01384513	A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies	Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00060424	Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT01839916	Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Therapeutic allogeneic lymphocytes	treatment	2	completed
NCT04941716	Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Acalabrutinib Tyrosine Venetoclax	treatment	2	recruiting
NCT02662296	Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant	Ibrutinib Idelalisib	treatment	2	withdrawn
NCT00078858	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT00104858	Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Cyclosporine Fludarabine Mycophenolate mofetil Rituximab	treatment	2	completed
NCT00014235	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT01093586	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Cyclosporine Methylprednisolone Methylprednisolone hemisuccinate Mycophenolate mofetil	treatment	2	completed
NCT00735930	Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Alvocidib Lenalidomide	treatment	1	completed
NCT01158274	RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors	Capecitabine RG-4733	treatment	1	completed
NCT00026182	Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	Edodekin alfa Natural Killer Cell Rituximab	treatment	2	completed
NCT01529827	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Fludarabine Melphalan Methotrexate Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00058227	Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma	Alvocidib Fludarabine Rituximab	treatment	1	completed
NCT00789776	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Natural Killer Cell Tacrolimus	treatment	1 / 2	completed
NCT00098891	MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas	Entinostat Isotretinoin	treatment	1	completed
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT01212380	Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)	Carfilzomib	treatment	1	completed
NCT04007029	Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	Cyclophosphamide Fludarabine Tocilizumab	treatment	1	recruiting
NCT01381692	Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	Bortezomib Bortezomib D-mannitol Dexamethasone Menthol Rituximab Sirolimus Temsirolimus	treatment	1 / 2	completed
NCT00010192	Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer	Aldesleukin Rituximab	treatment	1	completed
NCT00101244	SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	Ispinesib	treatment	1	terminated
NCT02285244	Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation	Sotrastaurin	treatment	2	withdrawn
NCT01682044	Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma	Filgrastim Pegfilgrastim Rituximab	treatment	2	completed
NCT00058240	Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma	Alvocidib	treatment	1 / 2	completed
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT00049504	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00891072	Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Carboplatin Isosorbide Paclitaxel	treatment	1	completed
NCT02254772	A Phase I/II Study of Intratumoral Injection of SD-101	Ipilimumab Toll-like receptor 9	treatment	1 / 2	completed
NCT00040846	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00060112	Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma	Gemcitabine	treatment	1	terminated
NCT00398112	Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Sunitinib	treatment	2	completed
NCT00003210	Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease	Edodekin alfa Natural Killer Cell	treatment	2	completed
NCT00017381	Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	Cyclophosphamide Filgrastim Rituximab	treatment	0	completed
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT04781855	Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation	Ibrutinib Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT00005950	506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma	Nelarabine	treatment	2	terminated
NCT01523223	Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies	Therapeutic allogeneic lymphocytes	treatment	1	completed
NCT00019708	Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	Tanespimycin	treatment	1	terminated
NCT01678443	Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies	Indium Yttrium Y-90	treatment	1	terminated
NCT01408043	Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma	Etoposide Filgrastim Plerixafor	treatment	Not Available	terminated
NCT00005803	Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	Beta-D-Glucose Carmustine Cyclophosphamide Cyclosporine Cytarabine Etoposide Fludarabine Mechlorethamine Mycophenolate mofetil	treatment	1 / 2	completed
NCT01326702	Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors	Bendamustine Rituximab Veliparib	treatment	1 / 2	completed
NCT00009984	Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer	Fludarabine Thalidomide	treatment	2	terminated
NCT02281279	Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma	Lenalidomide Rituximab Romidepsin	treatment	1 / 2	withdrawn
NCT00538187	Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma	Bortezomib Bortezomib D-mannitol Obatoclax	treatment	1	terminated
NCT06191887	B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT00918333	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma	Everolimus Panobinostat	treatment	1 / 2	completed
NCT01959477	Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant	Busulfan Cyclophosphamide Etoposide	treatment	0	completed
NCT01261247	Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Panobinostat	treatment	2	completed
NCT01044745	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Rituximab Tacrolimus	treatment	2	terminated
NCT01527045	Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies	Atorvastatin Cyclosporine Fludarabine Mycophenolate mofetil	prevention	2	completed
NCT00012298	Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Filgrastim Ibritumomab tiuxetan Oprelvekin Rituximab	treatment	1 / 2	terminated
NCT00343798	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT00058305	Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation	Bryostatin 1 Sulfate ion Vincristine	treatment	2	completed
NCT00096005	Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT02756897	Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia	Ibrutinib Venetoclax	treatment	2	active_not_recruiting
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT03045328	Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL	Ibrutinib Venetoclax	treatment	2	completed
NCT00711828	Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma	Bortezomib Cyclophosphamide Dexamethasone Rituximab	treatment	2	completed
NCT01769911	Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma	6-O-benzylguanine Carmustine Cytarabine Etoposide Melphalan	treatment	Not Available	withdrawn
NCT00089011	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00499811	Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction	Vorinostat	treatment	1	completed
NCT00089271	17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas	Alvespimycin	treatment	1	completed
NCT00079378	Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	2'-Deoxycytidine Decitabine Valproic acid	treatment	1	completed
NCT00947388	Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)	Alemtuzumab Bendamustine	treatment	1	terminated
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Fludarabine Melphalan	treatment	Not Available	completed
NCT00769288	FAU in Treating Patients With Advanced Solid Tumors or Lymphoma	No drug interventions	treatment	1	completed
NCT02168907	CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Bendamustine Devimistat Lipoic acid Rituximab	treatment	1	terminated
NCT02037256	Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma	Bortezomib Bortezomib D-mannitol Filgrastim	treatment	Not Available	completed
NCT00348985	PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas	Belinostat Bortezomib Bortezomib D-mannitol	treatment	1	completed
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT00621452	Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma	Aldesleukin Cyclophosphamide	treatment	1	completed
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Filgrastim Plerixafor	treatment	Not Available	terminated
NCT00118170	Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	Sorafenib	treatment	1	completed
NCT00601718	Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Carboplatin Etoposide Ifosfamide Rituximab Vorinostat	treatment	1 / 2	completed
NCT01231919	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia	No drug interventions	treatment	1	completed
NCT01658319	Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies	Fludarabine Methoxyamine	treatment	1	completed
NCT00004241	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma	Tanespimycin	treatment	1	completed
NCT01865617	Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia	No drug interventions	treatment	1 / 2	completed
NCT02109224	Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection	Ibrutinib	treatment	1	terminated
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	Abemaciclib Abiraterone Afatinib Albumin human Avobenzone Bevacizumab Bicalutamide Bortezomib Bortezomib D-mannitol Cabazitaxel Cabozantinib Capecitabine Carboplatin Celecoxib Cobimetinib Copanlisib Dabrafenib Dacomitinib Darolutamide Dasatinib Daunorubicin Doxorubicin Durvalumab Enasidenib Entrectinib Enzalutamide Erlotinib Everolimus Fluorouracil Idelalisib Imatinib Ipilimumab Lenvatinib Leucovorin Lorlatinib Losartan Neratinib Nivolumab Octinoxate Olaparib Oxaliplatin Paclitaxel Palbociclib Panobinostat Pembrolizumab Pertuzumab Ponatinib Regorafenib Ruxolitinib Sirolimus Sorafenib Sunitinib Trametinib Trastuzumab emtansine Tretinoin Vemurafenib Venetoclax Vismodegib Vorinostat	treatment	1	terminated
NCT00003196	Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma	Cyclosporine Mycophenolate mofetil Therapeutic allogeneic lymphocytes	treatment	Not Available	completed
NCT03010358	Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	Entospletinib Obinutuzumab	treatment	1 / 2	completed
NCT01110135	Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma	Bendamustine Dexamethasone Etoposide Filgrastim	treatment	2	completed
NCT00005786	Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia	Arsenic trioxide Arsenous acid	treatment	Not Available	terminated
NCT00054639	Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma	Rituximab	treatment	2	completed
NCT01769222	Ipilimumab and Local Radiation for Selected Solid Tumors	Ipilimumab	treatment	1	terminated
NCT01273766	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies	Deferasirox	supportive_care	2	completed
NCT00006473	Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Oxaliplatin	treatment	2	completed
NCT01515176	Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia	Dinaciclib Ofatumumab	treatment	1 / 2	completed
NCT01008462	Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia	Beta-D-Glucose Carmustine Cyclophosphamide Cytarabine Etoposide Fludarabine Mechlorethamine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00275080	Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia	2'-Deoxycytidine Decitabine Vorinostat	treatment	1	completed
NCT00438880	Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma	Agatolimod Rituximab	treatment	1 / 2	completed
NCT02153580	Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia	Bendamustine Beta-D-Glucose Cyclophosphamide Etoposide Fludarabine	treatment	1	active_not_recruiting
NCT02332980	Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	Ibrutinib Idelalisib Pembrolizumab	treatment	2	completed
NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT00867529	Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma	Rituximab	treatment	2	completed
NCT02005289	Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL	Lenalidomide Tafasitamab	treatment	2	active_not_recruiting
NCT00119392	Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Cyclosporine Fludarabine Mycophenolate mofetil Rituximab	treatment	2	completed
NCT02303392	Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma	Escitalopram Ibrutinib Selinexor	treatment	1	unknown_status
NCT02007044	Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia	Ibrutinib Rituximab	treatment	2	active_not_recruiting
NCT00288067	Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Fenretinide Rituximab	treatment	1 / 2	terminated
NCT00536601	High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors	Busulfan Carboplatin Carmustine Cyclophosphamide Etoposide Melphalan Thiotepa	treatment	Not Available	completed
NCT00105001	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Sirolimus Tacrolimus	treatment	2	completed
NCT04230304	Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study	Daratumumab Ibrutinib	treatment	2	active_not_recruiting
NCT00290472	CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	Menthol Temsirolimus	treatment	2	completed
NCT03961672	Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Duvelisib	treatment	2	active_not_recruiting
NCT00103272	17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT00017472	Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia	Apolizumab	treatment	1	completed
NCT03479268	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	Ibrutinib Pevonedistat	treatment	1	active_not_recruiting
NCT01995669	Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma	Lenalidomide Obinutuzumab	treatment	1 / 2	completed
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT03003546	Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial	Paclitaxel Rituximab	treatment	1	completed
NCT02420912	Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation	Ibrutinib Nivolumab	treatment	2	completed
NCT02928510	Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma	Idelalisib	Not Available	Not Available	terminated
NCT00022581	Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Thalidomide	treatment	2	completed
NCT01427881	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Busulfan Cyclophosphamide Cyclosporine Fludarabine	treatment	2	completed
NCT01419795	Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant	Lenalidomide Rituximab	treatment	2	terminated
NCT00072514	Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies	Carboplatin Dexamethasone Gemcitabine Rituximab	treatment	2	completed
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	withdrawn
NCT01789255	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies	Cyclosporine Methotrexate Tacrolimus Vorinostat	supportive_care	2	completed
NCT00077155	Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma	Cilengitide	treatment	1	completed
NCT00112723	Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma	Alvocidib	treatment	1 / 2	terminated
NCT02614508	Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	Buparlisib Ibrutinib Ofatumumab	treatment	1	terminated